Sees Q1 revenue down 3%, consensus $3.61B. The company expects sales to decline approximately 3% on a reported basis and 1% on a constant currency basis. The company expects U.S. GAAP earnings of $0.14 to $0.18 per diluted share and adjusted earnings, before special items, of $0.46 to $0.50 per diluted share.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BAX:
- Baxter Crumbles as Projections Disappoint, Job Cuts Planned
- Notable companies reporting before tomorrow’s open
- Baxter price target lowered to $60 from $73 at KeyBanc
- Miromatrix MiroliverELAP timeline pushed out two or three quarters, says Piper
- Miromatrix Medical, Baxter enter research agreement for ALF
